Search

Introduction: Tigecycline Evaluation and Surveillance Trail (TEST) study is an on-going global surveillance. The study was performed to determine the susceptibility of common pathogens to tigecycline and comparator antibiotics by broth microdilution (BMD) at two tertiary care centres in India from 2015 to 2017. Methodology: Total of 989 isolates collected from various clinical specimens between January 2015 and September 2017 from two centres in India were included. BMD was performed to determine the minimum inhibitory concentration (MIC) for tigecycline and comparator antibiotics. Results: Among Gram-negative bacteria, susceptibility to tigecycline was lowest among Klebsiella spp. being 84% while others such as E. coli, Enterobacter spp., Serratia spp. and H. influenzae showed susceptibility of 98%, 95%, 98% and 100% respectively. Overall, 99 isolates among Enterobacteriaceae (E. coli, Klebsiella spp. and Enterobacter spp.) were ESBL producers, susceptible to tigecycline. Among the 101 meropenem resistant Enterobacteriaceae, 85 were susceptible to tigecycline (84%). Among the Gram-positive bacteria, S. aureus and Enterococcus spp. were 99% and 98% susceptible to tigecycline respectively. Among 68 MRSA isolates in the study, 66 (97%) were susceptible to tigecycline. Seven vancomycin resistant E. faecalis were isolated and all were susceptible to tigecycline. Conclusion: Tigecycline has retained activity over both Gram-positive and Gram-negative organisms with MIC values comparable to global reports. About 98% of the MDR Gram-positive and Gram-negative bacteria in the study are susceptible to tigecycline. With increased incidence of extensively drug resistant organisms, tigecycline is a potential reserve drug. [ABSTRACT FROM AUTHOR]

Background: Lobeglitazone is a novel thiazolidinedione class of drug, acts by activating PPARγ in type 2 diabetes (T2DM). Evidence regarding its efficacy and safety is not available in Indian T2DM patients. Aims: To evaluate efficacy and safety of a novel thiazolidinedione, Lobeglitazone, in patients with T2DM uncontrolled on metformin. Methods: This was a 16-week randomized, double blind, double dummy, active controlled study which primarily evaluated change in HbA1c from baseline in Lobeglitazone (0.5 mg OD) compared to Pioglitazone (15 mg OD). Secondary endpoints were change in fasting (FBS) and post-prandial blood sugar (PBS). 12-week analysis results are presented here. Results: 317 patients were randomized to Lobeglitazone (N = 158) and Pioglitazone (N = 159) groups. HbA1c reduction from baseline to week 12 seen in Lobeglitazone group was 0.84% (baseline 8.6%) and in Pioglitazone group it was 0.74% (baseline 8.7%), p-value for non-inferiority being <0.0001. Secondary endpoints are mentioned in [Table 1]{Table 1} Reduction values mentioned are least square mean values. Conclusion: Lobeglitazone significantly improved the glycemic parameters and was well tolerated. Change in fasting insulin, HOMA-IR and HOMA-β in Lobeglitazone group was comparable to Pioglitazone. Lobeglitazone was found to be non-inferior to Pioglitazone in metformin uncontrolled T2DM patients. [ABSTRACT FROM AUTHOR]